Safety Data Sheet (United States)

Brepocitinib tosylate

#### 1.Identification

Product name: Brepocitinib tosylate

Catalog#: 4636EH

IUPAC name: [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimi

din-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone;4-methylbenzenesulfonic acid

Product use Only for research and development use by, or directly under the supervision of, a

restrictions: technically qualified individual.

Company: AK Scientific, Inc.

30023 Ahern Ave.

Union City, CA 94587

Telephone: (510) 429-8835 Fax: (510) 429-8836 Website: www.aksci.com

Emergency 1-800-633-8253 United States & Canada

contact number: 1-801-629-0667 International

#### 2. Hazard Identification:

### **GHS Classification (United States)**

Skin irritation (Category 2) Eye irritation (Category 2A)

Specific target organ toxicity - single exposure (Category 3), Respiratory system

## Pictogram(s)



## Signal word:

Warning

Hazard statement(s)

H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.

#### **Precautionary statement(s):**

P261 Avoid breathing dust/fume/gas/mist/vapors/spray.

P264 Wash skin thoroughly after handling.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352 IF ON SKIN: Wash with plenty of soap and water.

P304+P340 IF INHALED: Remove to fresh air and keep at rest in a position comfortable for

breathing.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,

if present and easy to do. Continue rinsing.

P312 Call a poison center or doctor if you feel unwell.

P321 Specific treatment (see supplemental first aid instructions on this label).

P332+P313 If skin irritation occurs: Get medical advice/attention. P337+P313 If eye irritation persists: Get medical advice/attention. Take off contaminated clothing and wash before reuse.

P403+P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

P501 Dispose of contents/container to an approved waste disposal plant.

Safety Data Sheet (United States)

Brepocitinib tosylate

## Hazards not otherwise classified (HNOC) or not covered by GHS:

None

### 3. Composition/Information on Ingredients

Synonyms: Brepocitinib tosylate; UNII-C960DPP15O; C960DPP15O; PF-06700841-15; Brepocitinib

tosylate (USAN)

CAS#: 2140301-96-6

Purity: 95%

EC: Not available.

#### 4. First Aid Measures

**General Information:** Immediately remove any clothing contaminated by the product. Move out of dangerous area. Consult a physician and show this safety data sheet.

**Inhalation:** Move person to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Obtain medical aid.

**Skin contact:** Immediately flush skin with running water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Obtain medical aid immediately.

**Eye contact:** Immediately flush open eyes with running water for at least 15 minutes. Obtain medical aid immediately.

**Ingestion:** Do NOT induce vomiting without medical advice. Rinse mouth with water. Never administer anything by mouth to an unconscious person. Obtain medical aid immediately.

Most important symptoms and effects, both acute and delayed: No further information available. Please see sections 2 and 11.

Indication of any immediate medical attention and special treatment needed: No further information available.

## 5. Fire Fighting Measures

Suitable extinguishing media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Specific hazards arising from the chemical: Carbon oxides, Hydrogen fluoride, Nitrogen oxides, Sulfur oxides.

**Advice for firefighters:** As in any fire, wear a NIOSH-approved or equivalent, pressure-demand, self-contained breathing apparatus and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.

#### 6. Accidental Release Measures

**Personal precautions, protective equipment and emergency procedures:** Wear protective equipment and keep unprotected personnel away. Ensure adequate ventilation. Remove all sources of ignition. Prevent further leak or spill if safe to do so. For personal protective equipment, please refer to section 8.

**Environmental precautions:** Do not let product enter drains, other waterways, or soil. **Methods and materials for containment and cleaning up:** Prevent further leak or spill if safe to do so. Vacuum, sweep up, or absorb with inert material and place into a suitable disposal container. Consult local regulations for disposal. See section 13 for further disposal information.

#### 7. Handling and Storage

**Precautions for safe handling:** Avoid contact with skin, eyes, and personal clothing. Wash hands thoroughly after handling. Avoid breathing fumes. Use only with adequate ventilation. Wear suitable protective clothing, gloves, and eye/face protection. Keep away from sources of ignition. Minimize dust

Safety Data Sheet (United States)

Brepocitinib tosylate

generation and accumulation. Keep container tightly closed. Open and handle container with care. Do not eat, drink, or smoke while handling.

Conditions for safe storage, including any incompatibilities: Store in a tightly-closed container when not in use. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep away from sources of ignition. ,Store long-term in a cool, dry place.

### 8. Exposure Controls/Personal Protection

**Exposure limits:** 

OSHA PEL: Not available. NIOSH REL: Not available. ACGIH TLV: Not available.

**Appropriate engineering controls:** Avoid contact with skin, eyes, and clothing. Wash hands before breaks and immediately after handling the product. Facilities storing or utilizing this material should be equipped with an eyewash fountain. Use adequate general and local exhaust ventilation to keep airborne concentrations low.

**Personal protection** 

Eyes:Not Available.Hands:Not Available.Skin and body:Not Available.Respiratory:Not Available.

9. Physical and Chemical Properties

Physical State: Not available. Molecular Formula: C25H29F2N7O4S

Molecular Weight: 561.6

Odor:
pH:
Not available.
Point Range:
Not available.
Not available.
Preezing/Melting Point:
Plash Point:
Not available.
Prevaporation Rate:
Not available.
Not available.
Not available.

Flammability(solid,gas): Please see section 2.

Explosive limits: Not available. Vapor Pressure: Not available. Vapor Density: Not available. Solubility: Not available. Relative Density: Not available. Refractive Index: Not available. Not available. Volatility: Auto-ignition Temperature: Not available. **Decomposition Temperature:** Not available. Partition Coefficient: Not available.

### 10. Stability and Reactivity

Reactivity: Not available.

Chemical stability: Stable under recommended temperatures and pressures.

Possibility of hazardous reactions: Not available. Conditions to avoid: Dust generation.

Incompatible materials: Strong oxidizing agents.

Hazardous decomposition products: Carbon oxides, Hydrogen fluoride, Nitrogen oxides, Sulfur oxides.

#### 11. Toxicological Information

RTECS# Not available. Acute toxicity: Not available.

Safety Data Sheet (United States)

Brepocitinib tosylate

Routes of exposure:

Symptoms related to the physical, chemical and toxicological characteristics:

Inhalation, eye contact, skin contact, ingestion. Skin contact may result in inflammation characterized by itching, scaling, reddening, blistering, pain or dryness. Eye contact may result in redness, pain or severe eye damage. Inhalation may cause irritation of the lungs and respiratory system. Overexposure may result in serious illness or death.

Carcinogenicity

IARC: Not classified.
NTP: Not listed.
OSHA: Not Available..

Acute toxic effects: Inflammation of the eye is characterized by redness, watering, and itching. Skin

inflammation is characterized by itching, scaling, reddening, or, occasionally,

blistering.

12. Ecological Information

Ecotoxicity: Not available.

Persistence and degradability: Not available.

Bioaccumulative potential: Not available.

Mobility in soil: Not available.

Other adverse effects: Not available.

13. Disposal Considerations

Disposal of waste:

Disposal of packaging:

Not listed

Not listed

14. Transportation Information

**DOT (United States)** 

UN number:
Proper shipping name:
Transport hazard class:
Packing group:

Not available.
Not available.
Not available.

**IATA** 

UN Number:
Proper shipping name:
Transport hazard class:
Packing group:

Not DG
Not available.
Not available.
Not available.

15. Regulatory Information

TSCA (United States)

Not Available.

California Proposition 65: Not Available..

NFPA Rating: Health: Not available.

Flammability: Not available. Instability: Not available.

16. Additional Information

Revision Date: 03/19/2022 Printed Date: 03/23/2022

The information above is believed to be accurate and represents the best information currently available

Safety Data Sheet (United States)

Brepocitinib tosylate

to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no event shall AK Scientific be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if AK Scientific has been advised of the possibility of such damages.